Literature DB >> 24416789

V-ATPase as an effective therapeutic target for sarcomas.

Francesca Perut, Sofia Avnet, Caterina Fotia, Serena Rubina Baglìo, Manuela Salerno, Shigekuni Hosogi, Katsuyuki Kusuzaki, Nicola Baldini.   

Abstract

Malignant tumors show intense glycolysis and, as a consequence, high lactate production and proton efflux activity. We investigated proton dynamics in osteosarcoma, rhabdomyosarcoma, and chondrosarcoma, and evaluated the effects of esomeprazole as a therapeutic agent interfering with tumor acidic microenvironment. All sarcomas were able to survive in an acidic microenvironment (up to 5.9–6.0 pH) and abundant acidic lysosomes were found in all sarcoma subtypes. V-ATPase, a proton pump that acidifies intracellular compartments and transports protons across the plasma membrane, was detected in all cell types with a histotype-specific expression pattern. Esomeprazole administration interfered with proton compartmentalization in acidic organelles and induced a significant dose-dependent toxicity. Among the different histotypes, rhabdomyosarcoma, expressing the highest levels of V-ATPase and whose lysosomes are most acidic, was mostly susceptible to ESOM treatment.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24416789

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  21 in total

Review 1.  Tumour acidosis: from the passenger to the driver's seat.

Authors:  Cyril Corbet; Olivier Feron
Journal:  Nat Rev Cancer       Date:  2017-09-15       Impact factor: 60.716

2.  Cancer-associated mesenchymal stroma fosters the stemness of osteosarcoma cells in response to intratumoral acidosis via NF-κB activation.

Authors:  Sofia Avnet; Gemma Di Pompo; Tokuhiro Chano; Costantino Errani; Arig Ibrahim-Hashim; Robert J Gillies; Davide Maria Donati; Nicola Baldini
Journal:  Int J Cancer       Date:  2017-03-15       Impact factor: 7.396

3.  Tumour-specific metabolic adaptation to acidosis is coupled to epigenetic stability in osteosarcoma cells.

Authors:  Tokuhiro Chano; Sofia Avnet; Katsuyuki Kusuzaki; Gloria Bonuccelli; Pierre Sonveaux; Dante Rotili; Antonello Mai; Nicola Baldini
Journal:  Am J Cancer Res       Date:  2016-03-15       Impact factor: 6.166

Review 4.  Recent Insights into the Structure, Regulation, and Function of the V-ATPases.

Authors:  Kristina Cotter; Laura Stransky; Christina McGuire; Michael Forgac
Journal:  Trends Biochem Sci       Date:  2015-10       Impact factor: 13.807

Review 5.  Rhabdomyosarcoma: Advances in Molecular and Cellular Biology.

Authors:  Xin Sun; Wei Guo; Jacson K Shen; Henry J Mankin; Francis J Hornicek; Zhenfeng Duan
Journal:  Sarcoma       Date:  2015-09-01

6.  Impairment of lysosomal activity as a therapeutic modality targeting cancer stem cells of embryonal rhabdomyosarcoma cell line RD.

Authors:  Manuela Salerno; Sofia Avnet; Gloria Bonuccelli; Shigekuni Hosogi; Donatella Granchi; Nicola Baldini
Journal:  PLoS One       Date:  2014-10-20       Impact factor: 3.240

Review 7.  Microenvironmental acidosis in carcinogenesis and metastases: new strategies in prevention and therapy.

Authors:  Stefano Fais; Giulietta Venturi; Bob Gatenby
Journal:  Cancer Metastasis Rev       Date:  2014-12       Impact factor: 9.264

8.  Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry.

Authors:  Jason Long; Edward Wright; Eleonora Molesti; Nigel Temperton; Wendy Barclay
Journal:  F1000Res       Date:  2015-01-29

9.  Curcumin-Loaded Nanoparticles Impair the Pro-Tumor Activity of Acid-Stressed MSC in an In Vitro Model of Osteosarcoma.

Authors:  Gemma Di Pompo; Margherita Cortini; Roberto Palomba; Valentina Di Francesco; Elena Bellotti; Paolo Decuzzi; Nicola Baldini; Sofia Avnet
Journal:  Int J Mol Sci       Date:  2021-05-28       Impact factor: 5.923

10.  Evidence-based support for the use of proton pump inhibitors in cancer therapy.

Authors:  Stefano Fais
Journal:  J Transl Med       Date:  2015-11-24       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.